Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01425879
Other study ID # NCI-2011-02974
Secondary ID NCI-2011-02974OS
Status Completed
Phase Phase 2
First received August 27, 2011
Last updated December 22, 2015
Start date April 2011
Est. completion date May 2014

Study information

Verified date December 2015
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the objective response rate (complete and partial response), as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria, in patients with advanced refractory biliary cancers (BC) receiving Akt inhibitor MK2206 (MK2206).

SECONDARY OBJECTIVES:

I. To determine the frequency and severity of adverse events and tolerability of the regimen in patients with advanced refractory BC receiving MK2206.

II. To determine the overall and progression-free survival of patients with advanced refractory BC receiving MK2206.

III. To determine the presence of genetic mutations of PI3-kinase/ Akt pathway signaling-pathway genes relevant to BC and how these correlate with objective response to treatment with MK2206.

IV. To determine the pharmacokinetic and pharmacogenetic profile as a way of assessing inter-individual variability as well as how these relate to clinical outcomes.

V. To determine genetic variants and mutations in genes encoding drug-metabolizing enzymes and transporters, and genes involved in tumor biology, and how these may be related to response to treatment.

OUTLINE: This is a multicenter study.

Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline and periodically during study for pharmacokinetic, pharmacogenetic, and other correlative studies. Previously collected tumor tissue is also analyzed.

After completion of study therapy, patients are followed up for 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 2014
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have histologically confirmed biliary tract carcinoma that is surgically unresectable

- Cytological confirmation is not allowed on this study, as tissue is needed for correlative science analysis

- Either fresh-frozen tissue (FFT) or paraffin-embedded tissue blocks (PETB) will be required from patients before enrolling on this study

- No biopsies will be required unless there is insufficient tissue or if the PETB available is more than 12 months old

- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with spiral CT scan (CT scan slice thickness no greater than 5 mm)

- Malignant lymph nodes will be considered measurable if they are = 15 mm in short axis

- Patients must have received one prior therapy for metastatic disease

- No prior Akt inhibitors allowed

- Patients with known brain metastases should be excluded from this clinical trial

- Life expectancy greater than 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =<2 (Karnofsky >= 60%)

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelet count >= 100,000/mcL

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT] =< 2.5 x IULN

- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (measured or calculated using the Cockroft-Gualt formula)

- Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

- Not pregnant or nursing

- Able to swallow oral tablets

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to Akt Inhibitor MK2206 (MK2206) or other agents used in the study

- Patients with diabetes or in risk for hyperglycemia should not be excluded from trials with MK2206, but the hyperglycemia should be well controlled on oral agents before the patient enters the trial

- Cardiovascular: baseline QTcF > 450 msec (male) or QTcF > 470 msec (female) will exclude patients from entry on study

- Patients with clinically significant bundle branch block or pre-existing clinically significant bradycardia will be excluded from the study

- No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements

- No concurrent grapefruit or grapefruit juice

- For patients having prior cryotherapy, radiofrequency ablation, ethanol injection, transarterial chemoembolization (TACE), or photodynamic therapy, the following criteria must be met:

- 6 weeks has elapsed since that therapy

- Indicator lesion(s) is/are outside the area of prior treatment or, if the only indicator lesion is inside the prior treatment area, there must be clear evidence of disease progression associated with that lesion

- Edges of the indicator lesion are clearly distinct on CT scanning

- Prior radiation therapy with or without the use of a fluoropyrimidine as a radiosensitizer in the adjuvant setting will be allowed on study if > 12 weeks have elapsed since therapy

- Prior palliative radiation therapy will allowed as long as > 4 weeks have elapsed since therapy

- No patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients may not be receiving any other investigational agents

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

- Patients receiving any medications or substances that are inhibitors or inducers of CYP 450 3A4 are ineligible

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Akt Inhibitor MK2206
Given PO
Other:
Diagnostic Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies

Locations

Country Name City State
United States Emory University/Winship Cancer Institute Atlanta Georgia
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio
United States Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland Ohio
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States M D Anderson Cancer Center Houston Texas
United States USC / Norris Comprehensive Cancer Center Los Angeles California
United States MedStar Georgetown University Hospital Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (complete and partial response) as defined by RECIST 1.1 Up to 4 weeks after completion of study treatment No
Secondary Frequency of adverse events related to MK-2206 Severity of adverse events is graded according to the NCI CTCAE 4.0. Up to 30 days after completion of study treatment Yes
Secondary Overall survival Analyzed using Kaplan-Meier plots. From study initiation to time of death, assessed up to 4 weeks after completion of study treatment No
Secondary Progression-free survival Analyzed using Kaplan-Meier plots. From start of treatment to time of documented progression or death whichever occurs first, assessed up to 4 weeks after completion of study treatment No
See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Completed NCT01900002 - Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT01899261 - Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery N/A
Completed NCT02234986 - A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma Phase 2
Completed NCT02578602 - MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer Phase 1
Completed NCT00608361 - Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Phase 1
Completed NCT02072486 - Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery N/A
Completed NCT01839604 - A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma Phase 1
Completed NCT04576572 - Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Recruiting NCT04022746 - An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer N/A
Completed NCT01666756 - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Phase 1
Completed NCT02409524 - An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects Phase 2
Recruiting NCT02418988 - Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma Phase 2
Terminated NCT01405573 - Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma Phase 3
Completed NCT01835223 - Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery Phase 1/Phase 2
Completed NCT01777594 - Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Phase 2
Completed NCT01829035 - A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC Phase 3
Active, not recruiting NCT02042443 - Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Phase 2
Completed NCT01015833 - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 3
Active, not recruiting NCT03211416 - Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer Phase 1/Phase 2